Hester Biosciences Limited has informed the Exchange about General Updates
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hester Biosciences has filed its FY 2025-26 corporate presentation, showcasing its position as one of Asia's largest animal vaccine producers. Consolidated revenue stands at Rs. 332.60 Cr with strong growth trajectory - sales grew from Rs. 235 Cr (FY22) to Rs. 332.60 Cr (FY26) on consolidated basis. The company operates across 35+ countries with 3 manufacturing plants in India, Nepal, and Tanzania. It is the world's largest PPR vaccine supplier, supplies to the WOAH PPR vaccine bank, and holds 35% poultry vaccine market share in India as the second-largest manufacturer. The presentation highlights business segments including Poultry Healthcare (62% of consolidated revenue) and Animal Healthcare (38%), with strategic focus on expanding its Petcare division in India.
The presentation demonstrates consistent revenue growth and strong market positioning in animal healthcare, which is positive for investor confidence. The company's diversified product portfolio and global footprint provide stability, though no specific forward-looking guidance was provided in this filing.